In this episode, Robert Sassoon, Managing Director and healthcare analyst at Water Tower Research, joins host Tim Gerdeman to discuss his newly published initiation of coverage on eXoZymes (Nasdaq: EXOZ) and its cell-free biomanufacturing platform.
Robert Sassoon explains how the technology works, the significance of the reported 10-fold productivity improvement in NCT manufacturing, and the next steps toward validating commercial-scale production with CDMO partner Curia Global. The conversation also covers NCT’s potential in the nutraceutical market, the competitive landscape, and the longer-term opportunity to develop novel molecules for pharmaceutical applications through the BioClick platform.
With an NCT product launch targeted for the first half of 2027, Robert Sassoon lays out the commercial, manufacturing, and regulatory milestones investors should watch as eXoZymes moves from pilot-scale validation to commercial execution.
Podden och tillhörande omslagsbild på den här sidan tillhör
Water Tower Research. Innehållet i podden är skapat av Water Tower Research och inte av,
eller tillsammans med, Poddtoppen.
